You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1
Chuanhai Cao
 -- 2250 2022-04-15 03:27:50 |
2 Format Change
Jessie Wu
 Meta information modification 2250 2022-04-15 03:43:07 | |
3 Format Change
Jessie Wu
 + 4 word(s) 2254 2022-04-15 04:22:38 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Cao, C.; Zieneldien, T.; , . The Role of Neuroprotective Plants in Alzheimer’s Disease. Encyclopedia. Available online: https://encyclopedia.pub/entry/21804 (accessed on 20 July 2025).
Cao C, Zieneldien T,  . The Role of Neuroprotective Plants in Alzheimer’s Disease. Encyclopedia. Available at: https://encyclopedia.pub/entry/21804. Accessed July 20, 2025.
Cao, Chuanhai, Tarek Zieneldien,  . "The Role of Neuroprotective Plants in Alzheimer’s Disease" Encyclopedia, https://encyclopedia.pub/entry/21804 (accessed July 20, 2025).
Cao, C., Zieneldien, T., & , . (2022, April 15). The Role of Neuroprotective Plants in Alzheimer’s Disease. In Encyclopedia. https://encyclopedia.pub/entry/21804
Cao, Chuanhai, et al. "The Role of Neuroprotective Plants in Alzheimer’s Disease." Encyclopedia. Web. 15 April, 2022.
The Role of Neuroprotective Plants in Alzheimer’s Disease
Edit
This entry is adapted from the peer-reviewed paper 10.3390/geriatrics7020024

Alzheimer’s disease (AD) is an age-related, progressive neurodegenerative disorder characterized by impaired cognition, memory loss, and altered personality. Many of the available pharmaceutical treatments do not alter the onset of disease progression. Recently, alternatives to developed drug candidates have been explored including medicinal plants and herbal treatments for the treatment of AD.

Alzheimer’s disease antioxidant

1. Alzheimer’s Disease  Pathological Mechanisms

Alzheimer's disease (AD) is a progressive age-related neurodegenerative disorder that is responsible for most cases of dementia [1]. Besides the environmental and genetic factors, which are presupposed to contribute to AD etiology, there are numerous hypotheses which have been elucidated to attempt to explicate AD. The most prevalent hypotheses are the Aβ cascade hypothesis, the inflammation hypothesis, the cholinergic hypothesis, the tau hypothesis, and the oxidative hypothesis [2][3][4]. The Aβ cascade hypothesis implicates Aβ peptides as the AD causative agent due to the extracellular deposition of the Aβ peptides as senile plaques, with the neurofibrillary tangles resulting in neuronal loss, dementia, and vascular damage [5]. Neurofribrillary tangles are also considered an AD hallmark and principally consist of tau, which is a microtubule-associated scaffold protein [6]. The aggregation of tau impairs the axons, leading to neurodegeneration [7]. Currently, the inflammation hypothesis has gained prominence as one of the major AD pathological factors, encompassing the immune response sustained in the brain [8]. Continuous activation of the brain’s immune cells, such as microglia, leads to the release and production of various proinflammatory cytokines, which aids tau and Aβ pathologies and leads to the loss of neurons [8]. Damage to the cholinergic neurons has also been accepted as a critical pathological chance associated with AD-related cognitive impairment [9]. As such, the cholinergic hypothesis proposes that cholinergic neuronal dysfunction in the brain could substantially contribute to the AD-related cognitive decline [9]. In general, this hypothesis is supported by the usage of cholinesterase inhibitors in the treatment of AD [10]. Furthermore, oxidative stress has also been determined to have a crucial role in AD pathogenesis [11]. In fact, a vast amount of evidence indicates that AD is perpetually accompanied by elevated oxidative cellular stress in the brain, yielded by the elevated production of free radicals, reduced polyunsaturated fatty acid, elevated protein and DNA oxidation, elevated lipid peroxidation, and the aggregation and accumulation of Aβ, which cause oxidative stress [12].

2. Herbal Neuroprotective Effects

Withania somnifera, common name ashwagandha, is an evergreen shrub in the Solanaceae family [13][14]. W. somnifera is one of the most conspicuous herbs prescribed for AD [15][16]. In general, it is prescribed as a nerve tonic and energy booster [16]. W. somnifera, as an adaptogen, has been demonstrated to possess free radical scavenging and antioxidant and immune-boosting activities [13]. W. somnifera contains a plethora of bioactive compounds of medical interest, such as withanolides A-Y, withanone, withasomniferols A-C, dehydrowithanolide-R, withasomidienone, and other ergostane-type steroidal lactones [17][18]. The plant also includes alkaloids, beta-sitosterol, and phytosterols sitoindosides VII-X [18]. Some of these constituents have been demonstrated to scavenge free radicals produced during AD pathological progression [18][19]. Molecular modeling research studies have elucidated that withanamides A and C have the ability to bind to the active motif of Abeta-25-35 and avert the formation of fibrils [20]. Subsequently, these compounds have been shown to protect neuronal rat cells and PC-12 cells from Beta-amyloid-induced neuronal death [21][22]. Consequently, therapeutic treatments that consist of W. somnifera’s methanol extractions have been shown to trigger the outgrowth of neurites in a time- and dose-dependent approach in human neuroblastoma cells [23]. Another research study consisting of cultured cortical rat neurons displayed a diminishment of pre- and postsynaptic stimuli, as well as dendritic and axonal atrophy, when treated with Aβ peptides [24]. Consequent therapeutic treatment with withanolide A displayed significant regenerative properties of dendrites and axons, and even displayed restorative properties of the pre- and postsynapses in the cultured neurons [24].
Withanolide A has been shown to inhibit Abeta25-35-induced axonal and dendritic degeneration in the hippocampus and cerebral cortex, while also seemingly restoring synapses and Aβ -peptide-induced memory impairment in mice [25]. Additionally, the ameliorative outcomes were retained after treatment discontinuation [25]. Subsequently, aqueous extracts of W. somnifera elevated the activity of choline acetyl transferase and acetylcholine in rats, potentially explicating the memory- and cognition-enhancing effects [23][26]. Consequently, root extract treatments led to low-density lipoprotein receptor-related protein upregulation, thereby boosting Aβ clearance and ameliorating AD pathology in APP/PS1 mice [27]. Similarly, administering semipurified extracts of W. somnifera orally inhibited Aβ peptide accumulation and reversed behavioral impairment in APP/PS1 mice models of AD [27]. These ameliorative effects were mediated via the enhancement of liver low-density lipoprotein receptor-related protein. Consequently, Drosophila melanogaster models of AD have also elucidated that W. somnifera treatment could mitigate Abeta toxicity while seemingly boosting longevity [28]. Nonetheless, although a vast amount of literature has reported the ameliorative therapeutic effects of W. somnifera, clinical data related to its use for cognitive impairment are limited [29].
In a double-blind, randomized, placebo-controlled study encompassing 50 subjects with mild cognitive impairment (MCI), the subjects were treated with 300 mg of W. somnifera root extracts twice daily or with a placebo for eight continuous weeks [30]. At the end of the eight weeks, the W. somnifera-treated group showed significant enhancements in information-processing speed, attention span, and executive function [30]. As such, these two studies provide evidence for W. somnifera’s enhancing roles in memory and executive function in subjects with MCI [27][30].
Bacopa monnieri, common names waterhyssop or brahmi, is a perennial plant in the Plantaginaceae family [31]. B. monnieri is a nootropic herb with low toxicity and has been traditionally utilized as a memory booster and neural tonic in a plethora of ailments [31]. There have been studies that have elucidated evidence for the role of B. monnieri in epilepsy, dementia, and Parkinson’s disease attenuation [32][33]. Furthermore, it has also been utilized for stress, asthma, and insomnia [34][35]. The bioactive phytochemicals present in B. monnieri encompass sterols, polyphenols, sulfhydryl compounds, saponins, bacosides A and B, betulic acid, bacopasides II, IV, and V, and bacosaponins A, B, C, D, and E [36]. The neuroprotective activity of B. monnieri could potentially be due to the bioactivity of the phytochemicals, thereby explaining its usage in traditional medicine. In fact, research studies conducted in vitro and in vivo demonstrate that these phytochemicals contain free radical scavenging and antioxidant activities via the blockage of lipid peroxidation in various brain areas [37][38]. B. monnieri elicits its role via the reduction in divalent metals, reduction in lipid peroxide formation, inhibition of lipoxygenase, and through its scavenging activity of reactive oxygen species [39].
Various studies have seemingly elucidated the role of B. monnieri in terms of intellect and memory [40][41]. In order to illuminate the neuroprotective activities of B. monnieri in rat models of AD, researchers conducted studies examining the administration of 20, 40, and 80 mg/kg alcoholic extracts of B. monnieri on rats for 2 weeks prior to and 1 week after intracerebroventricular ethylcholine aziridinium ion administration [42]. The Morris water maze was utilized to test spatial memory, and histological assays were utilized to assess the density of cholinergic neurons [42]. In this case, the B. monnieri extract appeared to enhance the escape latency time in the Morris water maze and blocked the diminishment of cholinergic neuron density [42]. Another conducted study demonstrated the backtracking of colchine-induced cognitive impairments by B. monnieri extracts [43]. Similarly, B. monnieri extracts attenuated oxidative damage caused by colchicine via the reduction in the protein carbonyl content while also restoring antioxidant enzyme activity [43].
The majority of the research studies examining the cognitive enhancement elicited by B. monnieri in humans have been centered on normal geriatric individuals. In a randomized, double-blind, placebo-controlled clinical trial encompassing 35 subjects of 55 years and older, the subjects were administered a 125 mg dosage of B. monnieri extract or a placebo twice a day for an interval of 12 weeks, with a placebo period that consisted of an additional four weeks [44]. The researchers conducted numerous memory tests focused on logical memory, visual reproduction, paired-association learning, general information, orientation, digit forward, and digit backward subtests [45]. The subjects were then given a score on each subtest, with the total memory consisting of the result of all of the subtests [44]. Treatment with B. monnieri extract significantly improved paired-association learning, mental control, and logical memory in the subjects in comparison to the placebo groups at 8 and 12 weeks following trial initiation [44]. These results propose that B. monnieri extracts could be beneficial in age-associated memory deficit treatment

3. Medicinal Plants for AD with Limited Studies

Currently, there are a plethora of other medicinal plants that show preventative and therapeutic activity for AD [46]. Nonetheless, in vitro and in vivo studies are limited, with most data deriving from observational studies. These plants include Commiphora wightii, Tinospora cordifolia, Hypericum perforatum, Rhodiola rosea, Moringa oleifera, Convolvolus pluricaulis, Hericium erinaceus, Camellia sinensis, and others [46][47][48][49][50][51]. Similarly, there are also neuroprotective natural products that could be obtained from food. To illustrate this, Allium sativum in the Alliaceae family has shown to be a potent anti-neuroinflammatory, antioxidant, and regulator of neurotransmitter signaling when referring to aged garlic extract, which could ameliorate AD pathogenesis [52][53]. Likewise, juice and extracts from Punica granatum have also shown neuroprotective effects in animal models, potentially by counteracting oxidative damage, minimizing inflammation of the brain and soluble Aβ 42 and hippocampal amyloid deposition [54][55].
Consequently, natural products, such as cannabidiol (CBD) and tetrahydrocannabinol (THC), have also shown to be effective in vitro and in vivo [56][57][58][59]. In PC12 neuronal cells, CBD has shown protection against oxidative stress, Aβ-induced neurotoxicity, inhibition of tau hyperphosphorylation, prevention of proinflammatory gene transcription, and inhibition of Aβ-induced tau hyperphosphorylation [60][61]. In vivo, CBD has shown attenuation of Aβ-induced neuroinflammatory responses by minimizing proinflammatory gene and mediator expression, as well as minimized reactive gliosis [59][62]. In vivo studies using CBD and THC have shown enhanced memory in the active avoidance and two-object recognition tasks [58]. Additionally, it has been shown to reduce soluble Abeta42 levels and alter the plaque composition [58].

4. Future Directions in Herbal Medicine

Currently, approximately 6.2 million Americans aged 65+ are suffering from Alzheimer’s dementia [63]. Additionally, that number is expected to grow to 13.8 million Americans by 2060 if effective therapeutics are not developed and utilized to halt, prevent, or slow AD-related pathogenesis [63]. Consequently, AD has an astoundingly high economic burden, with an approximated USD 305 billion having been spent on AD treatment in 2020 [64]. As such, finding effective therapeutic treatments are necessary to enhance patient outcomes. Even though various novel approaches have been found for symptomatic treatment and numerous disease-modifying therapies are under development, most clinical trials related to AD have not been successful [65]. Due to this, a significant deviation from monotherapeutic treatments has taken place to favor multitherapeutic, individualized, and comprehensive approaches since AD is a highly heterogeneous disorder [66][67].
Tau and Aβ have been shown to boost the loss of blood–brain–barrier (BBB) integrity [68]. Thus, a critical challenge in AD drug delivery relies on circumventing the BBB, which averts the entry of a plethora of possible therapeutic agents [68]. In general, the most common administration route is oral, but it has not been clearly elucidated whether herbal components can access the central nervous system from systemic circulation. Furthermore, rapid metabolism, limited solubility in aqueous environment, and incomplete distribution in the CNS are further limits that must be overcome. Thus, intranasal administration is an efficient and noninvasive administration route that could bypass the BBB and directly target the central nervous system [69]. Utilizing this method of delivery, herbs in medicated oil or dry powder forms could be administered directly to the subject. Medicated oils could also contain a mixture of lipid-soluble and lipophilic molecules to warrant the synergistic interactions between the varied herbal components. The benefits of intranasal delivery comprise brain injury avoidance, surmounting the requirement of implanting delivery devises, and reducing the systemic-administration-associated side effects [69][70]. Utilizing the intranasal administration technique, researchers have successfully treated memory loss in transgenic mice models of AD [71]. However, this method also has some limitations, such as a particularly small volume of administrated drugs, the limited surface area in the olfactory epithelium, and a relatively short retention time for drug absorption [72][73]. Thus, further research is required to support and enhance the usage of intranasal administration for herbal delivery.
In general, a large amount of evidence has shown that various herbs and natural bioactive products could be effective in AD treatment while having minimal severe adverse effects [74]. Even though it is not fully understood, the AD pathological process is proposed to be multifactorial [75]. As such, neuroprotective techniques encompassing a plethora of mechanisms of action are crucial for AD treatment and prevention. Natural product extracts and mixtures, with various bioactive compounds and neuroprotective mechanisms, are advantageous in drug discovery for AD. However, more research is necessary to address the concerns associated with herbal medicine and natural medicine for AD. Consequently, although the use of some herbs, such as those of C. longa and B. monnieri, have demonstrated slight clinical improvements, many natural products such as polyphenols remain of interest in the treatment of neurodegenerative disorders [76]. Additionally, some limitations include chemical instability, since curcumin and resveratrol are chemically unstable [77]. Likewise, low bioavailability, such as that observed with curcumin, is also a major issue [78]. Therefore, it has been challenging to translate effective preclinical results. Nonetheless, numerous studies have attempted to improve bioavailability by employing nanocarriers and nanotechnology, which could potentially enhance clinical efficacy and therapeutic response [79]. One notable example has been that of nanolipid epigallocatechin-3-gallate particles, which have demonstrated the ability to increase α-secretase, enhancing their ability in vitro and increasing epigallocatechin-3-gallate’s oral bioavailability by greater than two-fold [80]. As such, more comprehensive quality control and practical guidelines, in addition to novel strategies and approaches to promote central nervous system access of the herbal neuroprotective agents, could potentially allow natural product therapy to play an essential role in AD preventative and therapeutic measures.

References

  1. Guerreiro, R.; Bras, J. The age factor in Alzheimer’s disease. Genome Med. 2015, 7, 106.
  2. Ricciarelli, R.; Fedele, E. The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind. Curr. Neuropharmacol. 2017, 15, 926–935.
  3. Maccioni, R.B.; Farías, G.; Morales, I.; Navarrete, L. The revitalized tau hypothesis on Alzheimer’s disease. Arch. Med. Res. 2010, 41, 226–231.
  4. Liu, P.P.; Xie, Y.; Meng, X.Y.; Kang, J.S. History and progress of hypotheses and clinical trials for Alzheimer’s disease. Signal Transduct. Target. Ther. 2019, 4, 29.
  5. Hardy, J.A.; Higgins, G.A. Alzheimer’s disease: The amyloid cascade hypothesis. Science 1992, 256, 184–185.
  6. Busche, M.A.; Wegmann, S.; Dujardin, S.; Commins, C.; Schiantarelli, J.; Klickstein, N.; Kamath, T.V.; Carlson, G.A.; Nelken, I.; Hyman, B.T. Tau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo. Nat. Neurosci. 2019, 22, 57–64.
  7. Frost, B.; Jacks, R.L.; Diamond, M.I. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 2009, 284, 12845–12852.
  8. Kinney, J.W.; Bemiller, S.M.; Murtishaw, A.S.; Leisgang, A.M.; Salazar, A.M.; Lamb, B.T. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer’s Dement. 2018, 4, 575–590.
  9. Francis, P.T.; Palmer, A.M.; Snape, M.; Wilcock, G.K. The cholinergic hypothesis of Alzheimer’s disease: A review of progress. J. Neurol. Neurosurg. Psychiatry 1999, 66, 137–147.
  10. Birks, J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev. 2006, 1, CD005593.
  11. Huang, W.J.; Zhang, X.; Chen, W.W. Role of oxidative stress in Alzheimer’s disease. Biomed. Rep. 2016, 4, 519–522.
  12. Markesbery, W.R. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic. Biol. Med. 1997, 23, 134–147.
  13. Singh, N.; Bhalla, M.; de Jager, P.; Gilca, M. An overview on ashwagandha: A Rasayana (rejuvenator) of Ayurveda. Afr. J. Tradit. Complement. Altern. Med. 2011, 8, 208–213.
  14. Zahiruddin, S.; Basist, P.; Parveen, A.; Parveen, R.; Khan, W.; Ahmad, S. Ashwagandha in brain disorders: A review of recent developments. J. Ethnopharmacol. 2020, 257, 112876.
  15. Dar, N.J. Neurodegenerative diseases and Withania somnifera (L.): An update. J. Ethnopharmacol. 2020, 256, 112769.
  16. Rao, R.V.; Descamps, O.; John, V.; Bredesen, D.E. Ayurvedic medicinal plants for Alzheimer’s disease: A review. Alzheimer’s Res. Ther. 2012, 4, 22.
  17. Matsuda, H.; Murakami, T.; Kishi, A.; Yoshikawa, M. Structures of withanosides I, II, III, IV, V, VI, and VII, new withanolide glycosides, from the roots of Indian Withania somnifera DUNAL. and inhibitory activity for tachyphylaxis to clonidine in isolated guinea-pig ileum. Bioorg. Med. Chem. 2001, 9, 1499–1507.
  18. Mishra, L.C.; Singh, B.B.; Dagenais, S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): A review. Altern. Med. Rev. 2000, 5, 334–346.
  19. Sumathi, S.; Padma, P.R.; Gathampari, S.; Vidhya, S. Free radical scavenging activity of different parts of withania somnifera. Anc. Sci. Life 2007, 26, 30–34.
  20. Kumar, S.; Harris, R.J.; Seal, C.J.; Okello, E.J. An aqueous extract of Withania somnifera root inhibits amyloid β fibril formation in vitro. Phytother. Res. 2012, 26, 113–117.
  21. Jayaprakasam, B.; Padmanabhan, K.; Nair, M.G. Withanamides in Withania somnifera fruit protect PC-12 cells from beta-amyloid responsible for Alzheimer’s disease. Phytother. Res. 2010, 24, 859–863.
  22. Parihar, M.S.; Hemnani, T. Phenolic antioxidants attenuate hippocampal neuronal cell damage against kainic acid induced excitotoxicity. J. Biosci. 2003, 28, 121–128.
  23. Kuboyama, T.; Tohda, C.; Zhao, J.; Nakamura, N.; Hattori, M.; Komatsu, K. Axon- or dendrite-predominant outgrowth induced by constituents from Ashwagandha. Neuroreport 2002, 13, 1715–1720.
  24. Tohda, C.; Kuboyama, T.; Komatsu, K. Dendrite extension by methanol extract of Ashwagandha (roots of Withania somnifera) in SK-N-SH cells. Neuroreport 2000, 11, 1981–1985.
  25. Kuboyama, T.; Tohda, C.; Komatsu, K. Neuritic regeneration and synaptic reconstruction induced by withanolide A. Br. J. Pharmacol. 2005, 144, 961–971.
  26. Tohda, C.; Kuboyama, T.; Komatsu, K. Search for natural products related to regeneration of the neuronal network. Neurosignals 2005, 14, 34–45.
  27. Sehgal, N.; Gupta, A.; Valli, R.K.; Joshi, S.D.; Mills, J.T.; Hamel, E.; Khanna, P.; Jain, S.C.; Thakur, S.S.; Ravindranath, V. Withania somnifera reverses Alzheimer’s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc. Natl. Acad. Sci. USA 2012, 109, 3510–3515.
  28. Halim, M.A.; Rosli, I.M.; Jaafar, S.S.M.; Ooi, H.-M.; Long, P.-W.; Shamsuddin, S.; Najimudin, N.; Azzam, G. Withania somnifera Showed Neuroprotective Effect and Increase Longevity in Drosophila Alzheimer’s Disease Model; Cold Spring Harbor Laboratory: Cold Spring Harbor, LI, USA, 2020.
  29. Ng, Q.X.; Loke, W.; Foo, N.X.; Tan, W.J.; Chan, H.W.; Lim, D.Y.; Yeo, W.S. A systematic review of the clinical use of Withania somnifera (Ashwagandha) to ameliorate cognitive dysfunction. Phytother. Res. 2020, 34, 583–590.
  30. Choudhary, D.; Bhattacharyya, S.; Bose, S. Efficacy and Safety of Ashwagandha (Withania somnifera (L.) Dunal) Root Extract in Improving Memory and Cognitive Functions. J. Diet. Suppl. 2017, 14, 599–612.
  31. Aguiar, S.; Borowski, T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res. 2013, 16, 313–326.
  32. Mathew, J.; Balakrishnan, S.; Antony, S.; Abraham, P.M.; Paulose, C.S. Decreased GABA receptor in the cerebral cortex of epileptic rats: Effect of Bacopa monnieri and Bacoside-A. J. Biomed. Sci. 2012, 19, 25.
  33. Jadiya, P.; Khan, A.; Sammi, S.R.; Kaur, S.; Mir, S.S.; Nazir, A. Anti-Parkinsonian effects of Bacopa monnieri: Insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson’s disease. Biochem. Biophys. Res. Commun. 2011, 413, 605–610.
  34. Sokołowska, L.; Bylka, W. Bacopa Monnieri-activity and applications in medicine. Wiad. Lek. 2015, 68, 358–362.
  35. Channa, S.; Dar, A.; Anjum, S.; Yaqoob, M.; Atta Ur, R. Anti-inflammatory activity of Bacopa monniera in rodents. J. Ethnopharmacol. 2006, 104, 286–289.
  36. Jeyasri, R.; Muthuramalingam, P.; Suba, V.; Ramesh, M.; Chen, J.T. Bacopa monnieri and Their Bioactive Compounds Inferred Multi-Target Treatment Strategy for Neurological Diseases: A Cheminformatics and System Pharmacology Approach. Biomolecules 2020, 10, 536.
  37. Limpeanchob, N.; Jaipan, S.; Rattanakaruna, S.; Phrompittayarat, W.; Ingkaninan, K. Neuroprotective effect of Bacopa monnieri on beta-amyloid-induced cell death in primary cortical culture. J. Ethnopharmacol. 2008, 120, 112–117.
  38. Chaudhari, K.S.; Tiwari, N.R.; Tiwari, R.R.; Sharma, R.S. Neurocognitive Effect of Nootropic Drug Brahmi (Bacopa monnieri) in Alzheimer’s Disease. Ann. Neurosci. 2017, 24, 111–122.
  39. Dhanasekaran, M.; Tharakan, B.; Holcomb, L.A.; Hitt, A.R.; Young, K.A.; Manyam, B.V. Neuroprotective mechanisms of ayurvedic antidementia botanical Bacopa monniera. Phytother. Res. 2007, 21, 965–969.
  40. Roodenrys, S.; Booth, D.; Bulzomi, S.; Phipps, A.; Micallef, C.; Smoker, J. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology 2002, 27, 279–281.
  41. Kumar, N.; Abichandani, L.G.; Thawani, V.; Gharpure, K.J.; Naidu, M.U.; Venkat Ramana, G. Efficacy of Standardized Extract of Bacopa monnieri (Bacognize®) on Cognitive Functions of Medical Students: A Six-Week, Randomized Placebo-Controlled Trial. Evid.-Based Complement. Altern. Med. 2016, 2016, 4103423.
  42. Uabundit, N.; Wattanathorn, J.; Mucimapura, S.; Ingkaninan, K. Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer’s disease model. J. Ethnopharmacol. 2010, 127, 26–31.
  43. Saini, N.; Singh, D.; Sandhir, R. Neuroprotective effects of Bacopa monnieri in experimental model of dementia. Neurochem. Res. 2012, 37, 1928–1937.
  44. Raghav, S.; Singh, H.; Dalal, P.K.; Srivastava, J.S.; Asthana, O.P. Randomized controlled trial of standardized Bacopa monniera extract in age-associated memory impairment. Indian J. Psychiatry 2006, 48, 238–242.
  45. Khazdair, M.R.; Boskabady, M.H.; Hosseini, M.; Rezaee, R.; Tsatsakis, A.M. The effects of Crocus sativus (saffron) and its constituents on nervous system: A review. Avicenna J. Phytomed. 2015, 5, 376–391.
  46. Perry, E.K.; Pickering, A.T.; Wang, W.W.; Houghton, P.J.; Perry, N.S. Medicinal plants and Alzheimer’s disease: From ethnobotany to phytotherapy. J. Pharm. Pharmacol. 1999, 51, 527–534.
  47. Adams, M.; Gmünder, F.; Hamburger, M. Plants traditionally used in age related brain disorders—A survey of ethnobotanical literature. J. Ethnopharmacol. 2007, 113, 363–381.
  48. Howes, M.J.; Houghton, P.J. Ethnobotanical treatment strategies against Alzheimer’s disease. Curr. Alzheimer Res. 2012, 9, 67–85.
  49. Nabavi, S.F.; Braidy, N.; Orhan, I.E.; Badiee, A.; Daglia, M.; Nabavi, S.M. Rhodiola rosea L. and Alzheimer’s Disease: From Farm to Pharmacy. Phytother. Res. 2016, 30, 532–539.
  50. Sutalangka, C.; Wattanathorn, J.; Muchimapura, S.; Thukham-mee, W. Moringa oleifera mitigates memory impairment and neurodegeneration in animal model of age-related dementia. Oxid. Med. Cell. Longev. 2013, 2013, 695936.
  51. Farooqui, A.A.; Farooqui, T.; Madan, A.; Ong, J.H.; Ong, W.Y. Ayurvedic Medicine for the Treatment of Dementia: Mechanistic Aspects. Evid.-Based Complement. Altern. Med. 2018, 2018, 2481076.
  52. Chauhan, N.B. Anti-amyloidogenic effect of Allium sativum in Alzheimer’s transgenic model Tg2576. J. Herb. Pharmacother. 2003, 3, 95–107.
  53. Ray, B.; Chauhan, N.B.; Lahiri, D.K. The “aged garlic extract” (AGE) and one of its active ingredients S-allyl-L-cysteine (SAC) as potential preventive and therapeutic agents for Alzheimer’s disease (AD). Curr. Med. Chem. 2011, 18, 3306–3313.
  54. Choi, S.J.; Lee, J.H.; Heo, H.J.; Cho, H.Y.; Kim, H.K.; Kim, C.J.; Kim, M.O.; Suh, S.H.; Shin, D.H. Punica granatum protects against oxidative stress in PC12 cells and oxidative stress-induced Alzheimer’s symptoms in mice. J. Med. Food 2011, 14, 695–701.
  55. Ahmed, A.H.; Subaiea, G.M.; Eid, A.; Li, L.; Seeram, N.P.; Zawia, N.H. Pomegranate extract modulates processing of amyloid-β precursor protein in an aged Alzheimer’s disease animal model. Curr. Alzheimer Res. 2014, 11, 834–843.
  56. Cao, C.; Li, Y.; Liu, H.; Bai, G.; Mayl, J.; Lin, X.; Sutherland, K.; Nabar, N.; Cai, J. The potential therapeutic effects of THC on Alzheimer’s disease. J. Alzheimer’s Dis. 2014, 42, 973–984.
  57. Scuderi, C.; Steardo, L.; Esposito, G. Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARγ involvement. Phytother. Res. 2014, 28, 1007–1013.
  58. Aso, E.; Sánchez-Pla, A.; Vegas-Lozano, E.; Maldonado, R.; Ferrer, I. Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice. J. Alzheimer’s Dis. 2015, 43, 977–991.
  59. Esposito, G.; Scuderi, C.; Valenza, M.; Togna, G.I.; Latina, V.; De Filippis, D.; Cipriano, M.; Carratù, M.R.; Iuvone, T.; Steardo, L. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS ONE 2011, 6, e28668.
  60. Vallée, A.; Lecarpentier, Y.; Guillevin, R.; Vallée, J.N. Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer’s disease. Acta Biochim. Biophys. Sin. 2017, 49, 853–866.
  61. Iuvone, T.; Esposito, G.; Esposito, R.; Santamaria, R.; Di Rosa, M.; Izzo, A.A. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J. Neurochem. 2004, 89, 134–141.
  62. Esposito, G.; Scuderi, C.; Savani, C.; Steardo, L., Jr.; De Filippis, D.; Cottone, P.; Iuvone, T.; Cuomo, V.; Steardo, L. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br. J. Pharmacol. 2007, 151, 1272–1279.
  63. Alzheimer’s Association. 2021 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2021, 17, 327–406.
  64. Wong, W. Economic burden of Alzheimer disease and managed care considerations. Am. J. Manag. Care 2020, 26, S177–S183.
  65. Rafii, M.S.; Aisen, P.S. Alzheimer’s Disease Clinical Trials: Moving Toward Successful Prevention. CNS Drugs 2019, 33, 99–106.
  66. Folch, J.; Petrov, D.; Ettcheto, M.; Abad, S.; Sánchez-López, E.; García, M.L.; Olloquequi, J.; Beas-Zarate, C.; Auladell, C.; Camins, A. Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment. Neural Plast. 2016, 2016, 8501693.
  67. Ngandu, T.; Lehtisalo, J.; Solomon, A.; Levälahti, E.; Ahtiluoto, S.; Antikainen, R.; Bäckman, L.; Hänninen, T.; Jula, A.; Laatikainen, T.; et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. Lancet 2015, 385, 2255–2263.
  68. Zenaro, E.; Piacentino, G.; Constantin, G. The blood-brain barrier in Alzheimer’s disease. Neurobiol. Dis. 2017, 107, 41–56.
  69. Türker, S.; Onur, E.; Ozer, Y. Nasal route and drug delivery systems. Pharm. World Sci. 2004, 26, 137–142.
  70. Keller, L.A.; Merkel, O.; Popp, A. Intranasal drug delivery: Opportunities and toxicologic challenges during drug development. Drug Deliv. Transl. Res. 2021, 1, 1–23.
  71. Miyake, M.M.; Bleier, B.S. The blood-brain barrier and nasal drug delivery to the central nervous system. Am. J. Rhinol. Allergy 2015, 29, 124–127.
  72. Erdő, F.; Bors, L.A.; Farkas, D.; Bajza, Á.; Gizurarson, S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res. Bull. 2018, 143, 155–170.
  73. Wu, H.; Hu, K.; Jiang, X. From nose to brain: Understanding transport capacity and transport rate of drugs. Expert Opin. Drug Deliv. 2008, 5, 1159–1168.
  74. Akhondzadeh, S.; Abbasi, S.H. Herbal medicine in the treatment of Alzheimer’s disease. Am. J. Alzheimer’s Dis. Other Demen. 2006, 21, 113–118.
  75. Iqbal, K.; Grundke-Iqbal, I. Alzheimer’s disease, a multifactorial disorder seeking multitherapies. Alzheimer’s Dement. 2010, 6, 420–424.
  76. Chen, X.; Drew, J.; Berney, W.; Lei, W. Neuroprotective Natural Products for Alzheimer’s Disease. Cells 2021, 10, 1309.
  77. Renaud, J.; Martinoli, M.G. Considerations for the Use of Polyphenols as Therapies in Neurodegenerative Diseases. Int. J. Mol. Sci. 2019, 20, 1883.
  78. Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of curcumin: Problems and promises. Mol. Pharm. 2007, 4, 807–818.
  79. Kumar, A.; Ahuja, A.; Ali, J.; Baboota, S. Curcumin-loaded lipid nanocarrier for improving bioavailability, stability and cytotoxicity against malignant glioma cells. Drug Deliv. 2016, 23, 214–229.
  80. Smith, A.; Giunta, B.; Bickford, P.C.; Fountain, M.; Tan, J.; Shytle, R.D. Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer’s disease. Int. J. Pharm. 2010, 389, 207–212.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Neurosciences
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Chuanhai Cao
,
Tarek Zieneldien
,
View Times: 893
Revisions: 3 times (View History)
Update Date: 15 Apr 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Academic Video Service
    Feedback